

BIOPORTO INVESTOR EVENT

Unlocking the Growth

BioPorto A/S**Wednesday, October 7, 2026**

BioPorto A/S is pleased to invite current shareholders, prospective investors, analysts, and other stakeholders to an investor event at the Company's headquarters.



DATE
Wednesday
October 7, 2026



TIME
3:00 PM - 5:30 PM
Registration from 2:30 PM



VENUE
BioPorto A/S
Tuborg Havnevej 15
2900 Hellerup, Denmark

What to expect

The event will provide an updated perspective on BioPorto's strategy, commercial progress, and growth opportunities. Participants will also have the opportunity to hear independent perspectives from leading clinical and financial experts and engage directly with BioPorto's management team.

* The event will be conducted in English. Questions and discussions may be held in English or Danish.



Strategy & Commercial Progress

Latest progress and strategic priorities



Adult Clinical Validation Study

An update on the study design & objectives



Updated KDIGO Guidelines

Clinical landscape and potential opportunities



Capital Market Perspective

External view on the investment case and future value drivers


[REGISTER TO ATTEND](#)

Please register using the event link provided with this invitation.
We look forward to welcoming you to BioPorto.

Personal data: BioPorto will collect your personal data in connection with your communication and interaction with us. You can read more about how BioPorto processes your personal data and about your rights in connection with our processing of your personal data in BioPorto's [data protection notice](#).

Program

WEDNESDAY, OCTOBER 7, 2026

- 
- | | |
|----------------|---|
| 2:30 - 3:00 PM | Registration, coffee, and refreshments |
| 3:00 - 3:20 PM | Company update and outlook
Carsten Buhl, Chief Executive Officer
Klaus Juhl Wulff, Chief Financial Officer

An update on BioPorto's recent commercial progress, strategic priorities, regulatory initiatives, and the Company's path towards sustainable growth and cash flow positivity. |
| 3:20 - 3:40 PM | Company update on Adult Clinical Validation Study

Dr. Andrew Allegretti, MD, MSc, of Massachusetts General Hospital, Director of Critical Care Nephrology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School Principal Investigator for the U.S. Adult Urine NGAL Validation Study (joining online)

An independent clinical perspective on the role of NGAL in AKI management and the potential implications of the updated KDIGO guidelines for patient care and future adoption of biomarker-guided diagnostics. |
| 3:40 - 4:10 PM | Structural Kidney Damage;
What the new KDIGO guidelines mean

Prof. Dr. Jun Oh, Medical Director of the Department of Ped Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany

An independent clinical perspective on NGAL in AKI management and the potential implications for patient care and adoption of biomarker-guided diagnostics. |
| 4:10 - 4:45 PM | Investing in Small Cap Healthcare:
A market perspective and the BioPorto case

Niels Granholm-Leth, Head of Equity Research, DNB Carnegie
Oliver Røst Bennebalte, Equity Analyst, DNB Carnegie

A discussion of the current Small Cap investment environment and an external perspective on BioPorto's investment case and future value drivers. |
| 4:45 - 5:00 PM | Q&A

Carsten Buhl, Chief Executive Officer
Klaus Juhl Wulff, Chief Financial Officer |
| 5:00 - 5:30 PM | Networking, refreshments,
and Q&A |